Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mr Matsumura of Terumo Calls For Regulatory Reform of Medical Devices
March 15, 2010
- Ms Shiono to Be Promoted to President of SSP
March 15, 2010
- Quintiles Starts Tissue Testing Services in China
March 15, 2010
- Switch OTC Drugs Market Up 2.3% to ¥157.1 Bil. in 2009: Fuji-Keizai
March 15, 2010
- Suzuken Ties Up with Frontier for Dispensing Pharmacy Business
March 15, 2010
- Deepest Price Cuts for Lanbaxy/I'rom's Amlodipine Generics
March 15, 2010
- CareNet Obtains Patent on e-Detailing Service
March 15, 2010
- Sawai to Boost Sales to ¥74 Bil. by March 2012
March 15, 2010
- Merger with Schering-Plough to Make Merck 8th Company in Japan
March 15, 2010
- New NHI Prices Applicable from April 1 Announced
March 15, 2010
- 12 Generics Priced Higher Than Their Originals
March 15, 2010
- Group Organized to Increase Awareness of COPD
March 15, 2010
- Price Reduction Rate Lowest for Eli Lilly, Highest for Chemiphar
March 15, 2010
- Don't Create Any More New Medical Schools: AJMC
March 15, 2010
- Astellas to Enhance Oncology Pipeline through TOB of OSI
March 15, 2010
- Double-Digit Price Cuts for 27 Products from 35 Leading Companies
March 15, 2010
- 3 Candidates for JMA President Election
March 15, 2010
- Pfizer Japan: Sales Up 2.6% despite Fall in Sales of Norvasc
March 15, 2010
- Premium Will Be Effective for Expediting Development of New Drugs, Indications: Mr Nagatsuma
March 15, 2010
- Shionogi Licenses Ospemifene from QuatRx
March 15, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…